Ofloxacin is a new fluorinated quinolone antibiotic with a broad spectrum of activity against a variety of gram-positive and -negative bacteria including Enterobacteriaceae, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus. In addition, ofloxacin has significant activity against Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycobacterium tuberculosis and this may give rise to new indications for the class of quinolone antibiotics. Clinical trials to date have demonstrated the efficacy of ofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, and sexually transmitted diseases. Adverse effects to ofloxacin are usually mild and include gastrointestinal, central nervous system, and hypersensitivity reactions. Significant drug interactions with ofloxacin have not been reported.
Get full access to this article
View all access options for this article.
References
1.
WolfsonJSHooperDC. Minireview: The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother1985; 28: 581–6.
2.
HooperDCWolfsonJS. Minireview: The fluoroquinolones: Pharmacology, clinical uses and toxicities in humans. Antimicrob Agents Chemother1985; 28: 716–21.
3.
ChuDTWFernandesPB. Minireview: Structure activity relationships of the fluoroquinolones. Antimicrob Agents Chemother1989; 33: 131–5.
4.
HayakawaI.AtarshiS.YokohamaS., Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother1986; 29: 163–4.
5.
ImamuraM.ShibamuraS.HayakawaI.OsadaY.Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob Agents Chemother1987; 31: 325–7.
6.
HooperDCWolfsonJS. Mode of action of the quinolone antimicrobial agents. Rev Infec Dis1988; 10 (suppl 1): S14–S20.
7.
MitsuhashiS.Comparative antibacterial activity of new quinolone carboxylic acid derivatives. Rev Infect Dis1988; 10 (suppl 1): S27–S31.
8.
ZweerinkMMEdisonA.Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother1986; 29: 598–601.
SmithJTRatcliffeNT. Ciprofloxacin and ofloxacin possess an extra bacterial mechanism absent from other 4-quinolone antibacterial agents (abstract). Program and abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1984: 977.
KingA.ShannonK.PhillipsI.The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin. J Antimicrob Chemother1985; 15: 551–8.
13.
McEwenA.RobertsG.In vitro activity of ofloxacin against isolates of Neisseria gonorrhoeae. J Antimicrob Chemother1988; 22 (suppl C): 21–5.
14.
AuckenthalerR.Michea-HamzehpovrM.PechereJC. In-vitro activity of newer quinolones against aerobic bacteria. J Antimicrob Chemother1986; 17 (suppl B): 29–39.
15.
BasseyCMBaltchALSmithRP. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 179 bacterial isolates. J Antimicrob Chemother1986; 17: 623–8.
16.
DigranesA.DibbWLBenonisenE.In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim. Chemotherapy1985; 31: 466–71.
17.
SmithSM. In-vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin and ofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother1986; 29: 325–6.
18.
RubinsteinE.MarkZ.KernenG.AlkanM.BergerS.BogokowskiB.Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and outpatients. Infection1986; 14 (suppl 4): S20–5.
19.
Adeyemi-DoroFABRotowaNA. Comparison of in-vitro activity of ofloxacin and gentamicin against isolates from hospitalized patients. Infection1986; 14 (suppl 4): S240–2.
20.
SatoK.InoueY.FujiiT.AoyamaH.MitsuhashiS.Antibacterial activity of ofloxacin and its mode of action. Infection1986; 14 (suppl 4): S226–30.
21.
GoossensH.De MolP.CoignauH., Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), Ru28965 (a new macrolide) and other agents against enteropathogens. Antimicrob Agents Chemother1985; 27: 388–92.
22.
GrunebergRNFelminghamD.O'HareMD, The comparative in-vitro activity of ofloxacin. J Antimicrob Chemother1988; 22 (suppl C): 9–19.
23.
PhillipsI.KingA.Comparative activity of the 4-quinolones. Rev Infect Dis1988; 10 (suppl 1): S70–6.
24.
MraovicM.Canic-RadojlovicM.The activity of ofloxacin against methicillin-resistant Staphylococcus aureus. Infection1986; 14 (suppl 4): S231–2.
25.
TorresA.Fernandez-RoblasR.MendezB.SorianoF.Comparative activity of ofloxacin and 7 other antimicrobials against urea-splitting microorganisms. Infection1986; 14 (suppl 4): S233–6.
26.
ChauPYLeungYKWwsNG. Comparative in-vitro antibacterial activity of ofloxacin and ciprofloxacin against some selected gram-positive and gram-negative isolates. Infection1986; 14 (suppl 4): S237–9.
27.
AznarJ.CaballeroMCLozanoMCDe MiguelC.PalomaresJCPereaEJ. Activities of new quinolone derivatives against genital pathogens. Antimicrob Agents Chemother1985; 27: 76–8.
28.
DelmeeM.AvesaniV.Comparative in-vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile. Antimicrob Agents Chemother1986; 29: 374–5.
29.
FenlonCHCynamonMH. Comparative in-vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob Agents Chemother1986; 29: 386–8.
30.
OsadaY.OgawaH.Antimycoplasmal activity of ofloxacin (D18280). Antimicrob Agents Chemother1983; 23: 509–11.
31.
BerlinOGWYoungLSBrucknerDA. In-vitro activity of fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother1987; 19: 611–5.
32.
DaviesS.SparhamPDSpencerRC. Comparative in-vitro activity of five fluoroquinolones against mycobacteria. J Antimicrob Chemother1987; 19: 605–9.
33.
YoungLSBerlinOGWInderliedCB. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med1987; 82 (4A): 23–6.
34.
TsukamuraM.In vitro antituberculosis activity of a new antibacterial substance, ofloxacin (DL8280). Am Rev Respir Dis1985; 131: 348–51.
35.
LeysenDCHaemersA.PattynSR. Minireview: Mycobacteria and the new quinolones. Antimicrob Agents Chemother1989; 33: 1–5.
36.
SaitoA.SawatariK.FukudaY., Susceptibility of Legionella pneumophilia to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother1985; 28: 15–20.
37.
WiseR.GriggsD.AndrewsJM. Pharmacokinetics of the quinolones in volunteers: A proposed dosing schedule. Rev Infect Dis1988; 10 (suppl 1): S83–9.
38.
WunandsWJAVreeTBBaarsAMVan HerwaardenCLA. Steady-state kinetics of the quinolone derivatives, ofloxacin, enoxacin, ciprofloxacin, and pefloxacin, during maintenance treatment with theophylline. Drugs1987; 34: 159–69.
39.
LockleyMRWiseR.DentJ.The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother1984; 14: 647–52.
40.
VerhoM.MalerczykV.DagrosaE.KornA.Dose linearity and other pharmacokinetics of ofloxacin: A new, broad-spectrum antimicrobial agent. Pharmatherapeutica1985; 4: 376–82.
41.
HofflerD.KoeppeP.Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function. Drugs1987; 34: 51–5.
42.
FillastreJPLeroyA.HumbertG.Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother1987; 31: 156–60.
43.
VerhoM.MalerczykV.DagrosaE.KornA.The effect of food on the pharmacokinetics of ofloxacin. Curr Med Res Opinion1986; 10: 166–71.
44.
WiseR.LockleyMR. The pharmacokinetics of ofloxacin and a review of its tissue penetration. J Antimicrob Chemother1988; 22 (suppl C): 59–64.
45.
LodeH.HoffkenG.OlschewskiP., Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother1987; 31: 1338–42.
46.
LodeH.HoffkenG.OlschewskiP., Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin. J Antimicrob Chemother1988; 22 (suppl C): 73–9.
47.
StahlJPCroizeJ.LefebvreMA, Diffusion of ofloxacin into the cerebrospinal fluid in patients with bacterial meningitis. Infection1986; 14 (suppl 4): S254–5.
48.
StubnerG.WeinrichW.BrandsU.Study of the cerebrospinal fluid penetrability of ofloxacin. Infection1986; 14 (suppl 4): S250–3.
49.
CouraudL.FourtillanJBSauxMCBryskierA.Du LaurierM. VincentDiffusion of ofloxacin into human lung tissue. Drugs1987; 34: 37–8.
50.
KazmierczakA.PechinotA.DuezJMHaasO.FavreJP. Biliary tract excretion of ofloxacin in man. Drugs1987; 34: 39–43.
51.
AubertJ.LefebvreMACouetW.MignotA.FourtillanJB. Diffusion of ofloxacin into the prostate and kidney (abstract). Proceedings of the International Symposium on New Quinolones, Geneva, 1986.
52.
SymondsJ.BoneM.TurnerA.JavaidA.Penetration of ofloxacin into bronchial secretions. Drugs1987; 34: 33–6.
53.
DubenW.StudentA.JablonskiM.MalottkeR.Zur Gewebekonzentration und Wirksamkeit von ofloxacin bei chirurgischen patienten. Infection1986; 14 (suppl 1): S70–2.
54.
WhittmannDHKotthausE.Further methodological improvement in antibiotic bone concentration measurements: Penetration of ofloxacin into bone and cartilage. Infection1986; 14 (suppl 4): S270–3.
55.
ClaesR.DusartY.DupontJCJeanbaptisteB.PodoorM.DouchampsJ.Diffusion of oral ofloxacin (HOE280) into human prostatic tissue: Assessment by an improved h-PL chromatographic method. Infection1986; 14 (suppl 4): S263–5.
56.
WhiteLOMacgowanAPLoveringAMReevesDSMackayIG. A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin-N-oxide in patients with chronic renal failure. Drugs1987; 34: 56–61.
57.
DagrosaEEVerhoM.MalerczykV.De LoozeS.HajduP.ToyoderaK.Multiple dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent. Clin Ther1986; 8: 632–45.
58.
DorflerA.SchulzW.BurkhardtF.ZichnerM.Pharmacokinetics of ofloxacin in patients on hemodialysis treatment. Drugs1987; 34: 62–70.
59.
WhiteLOMacgowanAPMackayIGReevesDS. The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin-N-oxide in haemodialysis patients with endstage renal failure. J Antimicrob Chemother1988; 22 (suppl C): 65–72.
60.
ChanMKChauPYChanWWN. Concentrations of ofloxacin in serum and peritoneal fluid of patients undergoing continuous ambulatory peritoneal dialysis (abstract). Proceedings of the International Symposium on New Quinolones, Geneva, 1986.
61.
GrassiC.GrassiG. GialdroniMangiarottiP.Clinical efficacy of ofloxacin in lower respiratory tract infections. Drugs1987; 34: 80–2.
62.
MoorhouseECClarkePC. Efficacy of ofloxacin in the treatment of lower respiratory tract infections in general practice. J Antimicrob Chemother1988; 22 (suppl C): 135–8.
63.
KobayshiH.Clinical evaluation of ofloxacin in lower respiratory tract infections. Infection1986; 14 (suppl 4): S279–82.
64.
EgedeF.KristensenI.A clinical comparative study of ofloxacin and pivampicillin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother1988; 22 (suppl C): 139–42.
65.
LamWKChauPYSoSYLeungYKChanJCKShamMK. A double-blind, randomized study comparing ofloxacin and amoxicillin in treating infective episodes of bronchiectasis. Infection1986; 14 (suppl 4): S290–2.
66.
DevogelaereR.MaesP.Ofloxacin in lower respiratory tract infections—a comparison with amoxicillin. Infection1986; 14 (suppl 4): S283–9.
67.
HarazimH.WimmerJ.MittermayerHP. An open randomized comparison of ofloxacin and doxycycline in lower respiratory tract infections. Drugs1987; 34: 71–3.
68.
MaesenFPVDaviesBIGeraedtsWHBaurC.The use of quinolones in respiratory tract infections. Drugs1987; 34: 74–9.
69.
SaitoA.KatsuM.SaitoA.SoejimaR.Ofloxacin in respiratory tract infection. A review of the results of clinical trials in Japan Drugs1987; 34: 83–9.
70.
TsukamuraM.NakamuraE.YoshiiS.AmanoH.Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis1985; 131: 352–4.
71.
BlockJMWalstadRABjertnaesAA, Ofloxacin versus trimethoprim-sulphamethoxazole in acute cystitis. Drugs1987; 34: 100–6.
72.
LudwigG.PautherH.Clinical experience with ofloxacin in upper and lower urinary tract infections. A comparison with co-trimoxazole and nitrofurantoin. Drugs1987; 34: 95–9.
73.
CoxCECallerySVTackKJ. Clinical experience with ofloxacin in urinary tract infection. Infection1986; 14 (suppl 4): S303–4.
74.
RugendorffEW. Open randomized comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections. Drugs1987; 34: 91–4.
75.
Kromann-AndersenB.SommerP.PersC.LarsenV.RasmussenF.Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections. J Antimicrob Chemother1988; 22 (suppl C): 143–7.
76.
Kromann-AndersenB.SommerP.PersC.LarsenV.RasmussenF.Clinical evaluation of ofloxacin versus ciprofloxacin in complicated urinary tract infections. Infection1986; 14 (suppl 4): S305–6.
77.
AznarJ.PradosR.HerreraA.Rodriguez-PichardoA.PereaEJ. Single doses of ofloxacin in uncomplicated gonorrhoea. Drugs1987; 34: 107–10.
78.
AriyaritC.PanikabutraK.ChitwarakornA.WongbaC.BuatiangA.Efficacy of ofloxacin in complicated gonorrhoea. Infection1986; 14 (suppl 4): S311–3.
79.
ChanASCTangKCFungKKNgTK. Single-dose ofloxacin in treatment of uncomplicated gonorrhoea. Infection1986; 14 (suppl 4): S314–5.
80.
JudsonFNBealsBSTackKJ. Clinical experience with ofloxacin in sexually transmitted disease. Infection1986; 14 (suppl 4): 309–10.
81.
TanphaichitraD.SahaphongS.SrimuangS.Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections. Infection1986; 14 (suppl 4): S321–3.
82.
WeidnerW.SchieferHGGarbeC.Acute nongonococcal epididymitis, etiological and therapeutic aspects. Drugs1987; 34: 111–7.
83.
BlackJRLongJMZwicklBE, Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection. Antimicrob Agents Chemother1989; 33: 167–70.
84.
NayagamATRidgwayGLOrielJD. Efficacy of ofloxacin in treatment of non-gonococcal urethritis in men and genital infections caused by Chlamydia trachomatis in men and women. J Antimicrob Chemother1988; 22 (suppl C): 155–8.
85.
RichmondSJBhattacharyyaMNMaitiH.ChowdhuryFHStirlandRMToothJA. The efficacy of ofloxacin against infection caused by Neisseria gonorrhoeae and Chlamydia trachomatis. J Antimicrob Chemother1988; 22 (suppl C): 149–53.
FransenL.AvontsD.PiotP.Treatment of genital chlamydial infection with ofloxacin. Infection1986; 14 (suppl 4): S318–20.
88.
KetterlR.BeckurtsT.StubingerB.ClaudiB.Ofloxacin treatment in the management of chronic osteitis. Drugs1987; 34: 124–30.
89.
KetterlR.BeckurtsT.StubingerB.ClaudiB.Use of ofloxacin in open fractures and in the treatment of posttraumatic osteomyelitis. J Antimicrob Chemother1988; 22 (suppl C): 159–66.
90.
ChristW.LehnertT.UlbrichB.Specific toxicologic aspects of the quinolones. Rev Infect Dis1988; 10 (suppl 1): S141–6.
91.
BlomerR.BruchK.KraussH.WacheckW.Safety of ofloxacin—adverse drug reactions reported during phase II studies in Europe and Japan. Infection1986; 14 (suppl 4): S332–4.
92.
KoverechA.PicariM.GranataF.FostiniR.TonioloD.RecchiaG.Safety profile of ofloxacin: The Italian data base. Infection1986; 14 (suppl 4): S335–6.
93.
JungstG.MohrR.Side effects of ofloxacin in clinical trials and in postmarketing surveillance. Drugs1987; 34 (suppl 1): 144–9.
94.
JungstG.MohrR.Overview of postmarketing experience with ofloxacin in Germany. J Antimicrob Chemother1988; 22 (suppl C): 167–75.
95.
LodeH.Drug Interactions with the quinolones. Rev Infect Dis1988; 10 (suppl 1): S132–6.
96.
GregoireSLGraselaTHJrFreerJPTackKJSchentagJJ. Inhibition of theophylline clearance by co-administered ofloxacin without alteration of theophylline effects. Antimicrob Agents Chemother1987; 31: 375–8.
97.
WijnandsWJAVreeTBVan Her WaardenCLA. Enoxacin decreases the clearance of theophylline in man. Br J Clin Pharmacol1985; 20: 583–8.
98.
SchwartzJ.JaureguiL.LettieriJ.BachmannK.Impact of ciprofloxacin on theophylline clearance and steady-state concentration in serum. Antimicrob Agents Chemother1988; 32: 75–7.
99.
ThomsonAHThomsonGDHepburnM.WhitingB.A clinically significant interaction between ciprofloxacin and theophylline. Eur J Clin Pharmacol1987; 33: 435–6.
100.
WijnandsWJAVreeTBVan Her WaardenCLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol1986; 22: 677–83.
101.
SanoM.YamamotoI.UedaJ.YoshikawaE.YamashinaH.GotoM.Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration. Eur J Clin Pharmacol1987; 32: 431–2.
102.
FourtillanJBGranierJ.Saint-SalviB., Pharmacokinetics of ofloxacin and theophylline alone and in combination. Infection1986; 14 (suppl 1): S67–9.
BowlesSKPopovskiZ.RybakMJBeckmanHBEdwardsDJ. Effect of norfloxacin on theophylline pharmacokinetics at steady-state. Antimicrob Agents Chemother1988; 32: 510–2.
105.
HoG.TierneyMGDalesRE. Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline. Clin Pharmacol Ther1988; 44: 33–8.
106.
StaibAHStilleW.DietleinG., Interaction between quinolones and caffeine. Drugs1987; 34 (suppl 1): 170–4.
